Creating novel therapeutics together
Partnerships with pharmaceutical and biotechnology companies and academia are key drivers to realising our vision to become a commercial biopharmaceutical company with an innovative edge that will provide patients with transformational new medicines. Our strategy is based on an open and collaborative model, in which we combine our internal antibody discovery capabilities with partners possessing world-leading scientific and medical expertise and novel technological capabilities.
Together we are discovering and developing novel human therapeutic antibodies to treat cancer
We collaborate with the Gates Foundation and its partners on vaccine discovery and development